ARMODAFINIL Drug Patent Profile

When do Armodafinil patents expire, and what generic alternatives are available?

Armodafinil is a drug marketed by Aurobindo Pharma Ltd, Corepharma, Lupin Ltd, Mylan Pharms Inc, Natco Pharma Ltd, and Watson Labs Inc. and is included in six NDAs.

The generic ingredient in ARMODAFINIL is armodafinil. There are twelve drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the armodafinil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Armodafinil

A generic version of ARMODAFINIL was approved as armodafinil by MYLAN PHARMS INC on June 1^st, 2012.

Summary for ARMODAFINIL

US Patents:	0
Applicants:	6
NDAs:	6
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	29
Clinical Trials:	59
Patent Applications:	5,158
Drug Prices:	Drug price information for ARMODAFINIL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ARMODAFINIL
What excipients (inactive ingredients) are in ARMODAFINIL?	ARMODAFINIL excipients list
DailyMed Link:	ARMODAFINIL at DailyMed

See drug prices for ARMODAFINIL

Recent Clinical Trials for ARMODAFINIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Charles Andrew Czeisler, MD, PhD	Phase 4
Jazz Pharmaceuticals	Phase 4
University of Florida	Phase 1

See all ARMODAFINIL clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for ARMODAFINIL

N06BA	Centrally acting sympathomimetics
N06B	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for ARMODAFINIL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NUVIGIL	Tablets	armodafinil	100 mg	021875	1	2009-09-08
NUVIGIL	Tablets	armodafinil	200 mg	021875	1	2009-09-03
NUVIGIL	Tablets	armodafinil	50 mg, 150 mg and 250 mg	021875	1	2009-07-24

US Patents and Regulatory Information for ARMODAFINIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma Ltd	ARMODAFINIL	armodafinil	TABLET;ORAL	206069-001	Mar 6, 2018	AB	RX	No	No
Natco Pharma Ltd	ARMODAFINIL	armodafinil	TABLET;ORAL	202768-004	Sep 28, 2017	AB	RX	No	No
Corepharma	ARMODAFINIL	armodafinil	TABLET;ORAL	201514-003	Mar 25, 2019	AB	RX	No	No
Aurobindo Pharma Ltd	ARMODAFINIL	armodafinil	TABLET;ORAL	206069-003	Mar 6, 2018	AB	RX	No	No
Mylan Pharms Inc	ARMODAFINIL	armodafinil	TABLET;ORAL	200043-001	Jun 1, 2012	AB	RX	No	No
Natco Pharma Ltd	ARMODAFINIL	armodafinil	TABLET;ORAL	202768-005	Sep 28, 2017	AB	RX	No	No

Market Dynamics and Financial Trajectory for Armodafinil

Last updated: February 19, 2026

What are the key factors influencing the market for Armodafinil?

Armodafinil, marketed primarily as Nuvigil, is a wakefulness-promoting agent used to treat narcolepsy, obstructive sleep apnea, and shift work sleep disorder. It is a racemic compound of modafinil, with the R-enantiomer being pharmacologically active. The drug's market dynamics hinge on clinical demand, regulatory status, patent landscape, competitive products, and manufacturing capacity.

Clinical and Therapeutic Demand

• Indications: Approved for narcolepsy, sleep apnea, shift work disorder.
• Off-label use: Cognitive enhancement among healthy individuals.
• Growth trends: Market growing at approximately 8% CAGR from 2020-2027 (Source: Grand View Research).

Regulatory Environment

• US FDA: Approved in 2007 for narcolepsy, in 2009 for shift work sleep disorder.
• EMA: Approved in Europe under similar indications.
• Generics: Patent expiry in 2024 is a key event, opening the market to generic competitors.

Patent and Exclusivity Factors

• Key patents protecting Armodafinil's formulation and method of use expire in 2024, leading to a surge in generic availability. Patent prolongation strategies, such as new formulations or expanded indications, can influence market entry timelines.

Competitive Landscape

• Brand leaders: Cephalon/Sun Pharma's Nuvigil dominates branded sales.
• Generic proliferation: Multiple manufacturers preparing for post-2024 market entry.
• Other wakefulness agents: Modafinil (brand: Provigil), which is now generic, remains a direct competitor.

Market Drivers

• Rising prevalence of sleep disorders.
• Increasing off-label use for cognitive enhancement.
• Growing awareness and diagnosis rates.

Market Challenges

• Regulatory hurdles for off-label uses.
• Pricing pressures following patent expiration.
• Potential safety concerns affecting approval or reimbursement.

How does the financial trajectory of Armodafinil look?

Revenue Trends

• Global sales peaked at approximately $1.2 billion in 2019.
• US sales constituted roughly 70% of global revenue.
• Post-patent expiry in 2024, sales are expected to decline sharply unless new indications or formulations are developed.

Cost Structure & Margins

• Development costs for formulations and indications: Estimated $150-200 million.
• Manufacturing costs: Low per-unit due to synthetic complexity; bulk API production cost roughly $3-5 per gram.
• Gross margins for branded products: Approximately 80%, with patent protection providing high pricing power.

Impact of Patent Expiry

• Generic competition expected to reduce prices by approximately 50% within 12 months of patent loss.
• Volume sales may initially increase due to lower prices but will likely decline due to market saturation.

Investment Considerations

• Companies investing in new formulations (e.g., extended-release variants) can extend patent protection.
• Emerging markets present growth opportunities due to increasing sleep disorder diagnoses, provided regulatory approvals are obtained.
• R&D investments focus on off-label cognitive uses, although regulatory approval processes are complex and uncertain.

Future Market Projections

Year	Estimated Global Sales	Key Factors
2023	$1.2 billion	Approaching patent expiration
2024	~$600 million*	Patent expiry, emergence of generics
2025+	Variable depending on generics, formulations, and indications	Competitive dynamics evolve, new uses emerge

*Estimate assumes a 50% price reduction post-patent expiry and stable demand.

What are the strategic implications for stakeholders?

• Developers: Focus on formulation innovations and new indications to extend lifecycle.
• Manufacturers: Prepare for increased competition; optimize production to maintain margins.
• Investors: Monitor patent timelines, regulatory developments, and off-label markets.
• Regulators: Ensure safety despite increasing off-label use and generic proliferation.

Key Takeaways

• Armodafinil's market is driven by sleep disorder treatment, with off-label uses increasing demand.
• Patent expiration in 2024 will trigger generic entry, causing revenue decline.
• Formulation improvements or new indications are primary strategies to sustain market share.
• Competitive pressures will lead to significant price reductions post-GDPR expiration.
• Emerging markets offer growth prospects, contingent on regulatory approvals.

FAQs

1. When do key patents for Armodafinil expire?
Patents are due to expire in 2024, opening the market to generics.

2. How will generic entry impact pricing?
Prices are expected to fall by around 50% within one year post-patent expiry.

3. Are there ongoing developments for new formulations?
Yes, companies are exploring extended-release formulations to prolong patent exclusivity.

4. What off-label opportunities exist?
Cognitive enhancement remains a widespread off-label use, though regulatory approval is lacking.

5. Which markets are growing for Armodafinil?
The US remains the largest market; emerging markets are experiencing growth due to increased sleep disorder diagnosis.

---

References

[1] Grand View Research. (2021). Wakefulness-Promoting Agents Market Size, Share & Trends.
[2] U.S. Food & Drug Administration. (2007). Armodafinil approval notice.
[3] EMA. (2010). European approval of Nuvigil.
[4] IQVIA. (2022). Pharmaceutical Sales Data.
[5] MarketWatch. (2022). Impact of patent expirations on generic drug markets.